224 related articles for article (PubMed ID: 28809778)
1. Reprimo, a Potential p53-Dependent Tumor Suppressor Gene, Is Frequently Hypermethylated in Estrogen Receptor α-Positive Breast Cancer.
Buchegger K; Riquelme I; Viscarra T; Ili C; Brebi P; Huang TH; Roa JC
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28809778
[TBL] [Abstract][Full Text] [Related]
2. Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.
Buchegger K; Ili C; Riquelme I; Letelier P; Corvalán AH; Brebi P; Huang TH; Roa JC
Biol Res; 2016 Jan; 49():5. PubMed ID: 26796959
[TBL] [Abstract][Full Text] [Related]
3. CpG island shore methylation regulates caveolin-1 expression in breast cancer.
Rao X; Evans J; Chae H; Pilrose J; Kim S; Yan P; Huang RL; Lai HC; Lin H; Liu Y; Miller D; Rhee JK; Huang YW; Gu F; Gray JW; Huang TM; Nephew KP
Oncogene; 2013 Sep; 32(38):4519-28. PubMed ID: 23128390
[TBL] [Abstract][Full Text] [Related]
4. [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation].
Tang B; Jiang J
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):283-7. PubMed ID: 16181550
[TBL] [Abstract][Full Text] [Related]
5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
6. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
[TBL] [Abstract][Full Text] [Related]
7. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
8. Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer.
Saavedra K; Valbuena J; Olivares W; Marchant MJ; Rodríguez A; Torres-Estay V; Carrasco-Avino G; Guzmán L; Aguayo F; Roa JC; Corvalán AH
PLoS One; 2015; 10(5):e0125834. PubMed ID: 25954972
[TBL] [Abstract][Full Text] [Related]
9. CpG methylation of the ERalpha and ERbeta genes in breast cancer.
Kim SJ; Kim TW; Lee SY; Park SJ; Kim HS; Chung KW; Lee ES; Kang HS
Int J Mol Med; 2004 Aug; 14(2):289-93. PubMed ID: 15254780
[TBL] [Abstract][Full Text] [Related]
10. Interplay of ERα binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells.
John Mary DJS; Sikarwar G; Kumar A; Limaye AM
Mol Cell Endocrinol; 2020 Mar; 504():110701. PubMed ID: 31926189
[TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.
Ung M; Ma X; Johnson KC; Christensen BC; Cheng C
Epigenetics; 2014 Apr; 9(4):523-32. PubMed ID: 24434785
[TBL] [Abstract][Full Text] [Related]
12. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
Gaudet MM; Campan M; Figueroa JD; Yang XR; Lissowska J; Peplonska B; Brinton LA; Rimm DL; Laird PW; Garcia-Closas M; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3036-43. PubMed ID: 19861523
[TBL] [Abstract][Full Text] [Related]
13. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
[TBL] [Abstract][Full Text] [Related]
14. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of Reprimo in lung cancer.
Suzuki M; Shigematsu H; Takahashi T; Shivapurkar N; Sathyanarayana UG; Iizasa T; Fujisawa T; Gazdar AF
Lung Cancer; 2005 Mar; 47(3):309-14. PubMed ID: 15713514
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of Reprimo in human malignancies.
Takahashi T; Suzuki M; Shigematsu H; Shivapurkar N; Echebiri C; Nomura M; Stastny V; Augustus M; Wu CW; Wistuba II; Meltzer SJ; Gazdar AF
Int J Cancer; 2005 Jul; 115(4):503-10. PubMed ID: 15700311
[TBL] [Abstract][Full Text] [Related]
17. p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.
Berger CE; Qian Y; Liu G; Chen H; Chen X
J Biol Chem; 2012 Aug; 287(36):30117-27. PubMed ID: 22787161
[TBL] [Abstract][Full Text] [Related]
18. A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes.
Ariazi EA; Taylor JC; Black MA; Nicolas E; Slifker MJ; Azzam DJ; Boyd J
Mol Cancer Res; 2017 Feb; 15(2):152-164. PubMed ID: 28108626
[TBL] [Abstract][Full Text] [Related]
19. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer.
Ooki A; Yamashita K; Yamaguchi K; Mondal A; Nishimiya H; Watanabe M
Mol Cancer Res; 2013 Nov; 11(11):1362-74. PubMed ID: 23982217
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM.
Malik S; Jiang S; Garee JP; Verdin E; Lee AV; O'Malley BW; Zhang M; Belaguli NS; Oesterreich S
Mol Cell Biol; 2010 Jan; 30(2):399-412. PubMed ID: 19917725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
